To test the hypothesis that the PGD2-GPR44/DP2 axis is activated in T2DM and can be a therapeutically relevant target in treatment of T2DM, a mechanistic clinical study was designed and executed using the oral GPR44/DP2 antagonist AZD1981. This evidence concerns the gene PTGDR2 and type 2 diabetes mellitus.